Deccan Healthcar

Has Deccan Healthcar declared dividend?

No Dividend History Available

What is the technical trend for Deccan Healthcar?

As of May 15, 2025, Deccan Healthcare's trend is mildly bearish, influenced by daily moving averages, while weekly indicators show mixed signals, suggesting a cautious outlook.

As of 15 May 2025, the technical trend for Deccan Healthcare has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating a bearish trend, while the weekly MACD and Bollinger Bands show a mildly bullish signal. The monthly indicators, including MACD and KST, remain bearish, suggesting underlying weakness. The RSI shows no signal on both weekly and monthly time frames, indicating a lack of momentum. Overall, the mixed signals across different time frames reflect a cautious outlook for the stock.

Who are the peers of the Deccan Healthcar?

Deccan Healthcar's peers include Jeevan Scienti., Centenial Surgic, Aspira Pathlab, N G Industries, Amkay Products, Bandaram Pharma, KMS Medisurgi, Medinova Diagno., and Tejnaksh Health. Centenial Surgic has the highest 1-year return at 39.83%, while Deccan Healthcar has the lowest at -42.18%.

Peers: The peers of Deccan Healthcar are Jeevan Scienti., Centenial Surgic, Aspira Pathlab, N G Industries, Amkay Products, Bandaram Pharma, KMS Medisurgi, Medinova Diagno., and Tejnaksh Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amkay Products, while Average management risk is found at Jeevan Scienti., N G Industries, KMS Medisurgi, and Bandaram Pharma, and the rest. Below Average management risk is noted at Centenial Surgic, Aspira Pathlab, Deccan Healthcar, Tejnaksh Health, and the rest. Growth is Excellent at Bandaram Pharma, Below Average at Jeevan Scienti., Centenial Surgic, Aspira Pathlab, N G Industries, Amkay Products, Deccan Healthcar, KMS Medisurgi, Tejnaksh Health, and the rest. Good capital structure is seen at Centenial Surgic, N G Industries, Amkay Products, Deccan Healthcar, KMS Medisurgi, and Tejnaksh Health, while Average capital structure is observed at Jeevan Scienti., Aspira Pathlab, and the rest, and Below Average at Bandaram Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Centenial Surgic at 39.83%, while the lowest is Deccan Healthcar at -42.18%. Deccan Healthcar's 1-year return is significantly lower than all its peers. Additionally, the peers with negative six-month returns include Deccan Healthcar, Bandaram Pharma, Aspira Pathlab, Tejnaksh Health, and N G Industries.

Who are in the management team of Deccan Healthcar?

As of March 2022, the management team of Deccan Healthcar includes Minto Gupta (Chairman & Managing Director), Meenakshi Gupta (Director), Ruchi Khattar (Independent Director), Kandlakunta Samhitha (Independent Director), and Ravi Ram Prasad (Director).

As of March 2022, the management team of Deccan Healthcar includes the following individuals:<BR><BR>1. Minto Gupta - Chairman & Managing Director<BR>2. Meenakshi Gupta - Director<BR>3. Ruchi Khattar - Independent Director<BR>4. Kandlakunta Samhitha - Independent Director<BR>5. Ravi Ram Prasad - Director<BR><BR>The team comprises a mix of executive and independent directors, with Minto Gupta serving as the Chairman and Managing Director.

What does Deccan Healthcar do?

Deccan Health Care Ltd is a micro-cap company in the healthcare services industry, reporting net sales of 208 Cr and a net profit of 1 Cr for March 2025. It has a market cap of INR 48 Cr and key financial metrics include a P/E ratio of 44.00 and a return on equity of 1.08%.

Overview: <BR>Deccan Health Care Ltd operates in the healthcare services industry and is classified as a micro-cap company.<BR><BR>History: <BR>Deccan Health Care Ltd was originally incorporated as a Public Limited Company in 1996. It underwent several status changes, becoming a Private Limited Company in 2009 and then reverting to a Public Company in 2017. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 208 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 48 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 44.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.02 <BR>Return on Equity: 1.08% <BR>Price to Book: 0.45 <BR><BR>Contact Details: <BR>Address: 247 2nd Flr Dwarakapuri Colony, Punjagutta Hyderabad Telangana : 500082 <BR>Tel: 91-040-40144508 <BR>Email: investors@deccanhealthcare.co.in <BR>Website: http://www.deccanhealthcare.co.in

Who are the top shareholders of the Deccan Healthcar?

The top shareholders of Deccan Healthcar include Minto Purshotam Gupta with 14.46%, Focal Ventures Private Limited at 9.69%, and individual investors holding a combined 47.83%. There are no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Deccan Healthcar include Minto Purshotam Gupta, who holds the largest stake at 14.46%. Following him, Focal Ventures Private Limited is the highest public shareholder with a 9.69% ownership. Additionally, individual investors collectively hold 47.83% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

How big is Deccan Healthcar?

As of 24th July, Deccan Health Care Ltd has a market capitalization of 49.00 Cr, with recent net sales of 75.06 Cr and a net profit of 1.15 Cr. The company's shareholder's funds are 96.91 Cr, and total assets amount to 108.05 Cr.

As of 24th July, Deccan Health Care Ltd has a market capitalization of 49.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 75.06 Cr and a Net Profit of 1.15 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 96.91 Cr and Total Assets of 108.05 Cr.

Are Deccan Healthcar latest results good or bad?

Deccan Health Care's latest results are positive, with a 6.70% increase in net sales and a 100% rise in net profit. However, despite these strong indicators, market analysts have issued a 'Strong Sell' recommendation, suggesting caution.

Deccan Health Care's latest results for the quarter ending June 2025 indicate a positive performance overall. The company reported its highest quarterly net sales to date, reaching Rs 22.14 crore, which reflects a growth of 6.70% compared to the previous quarter. Additionally, the net profit saw a remarkable increase of 100%, a significant turnaround from the previous quarter's decline.<BR><BR>The inventory turnover ratio has also improved, indicating that the company is effectively managing its inventory. This is a positive sign for operational efficiency. However, despite these encouraging financial indicators, MarketsMOJO has issued a 'Strong Sell' recommendation on the stock, which suggests some caution from market analysts.<BR><BR>In summary, while the financial results show strong growth and improved performance metrics, the market sentiment appears to be more cautious.

Is Deccan Healthcar overvalued or undervalued?

As of October 6, 2025, Deccan Healthcare's valuation has improved to attractive, indicating it is undervalued with a PE ratio of 42.12, an EV to EBITDA of 13.43, and a low EV to Book Value of 0.41, especially when compared to peers like Sun Pharma and Cipla.

As of 6 October 2025, the valuation grade for Deccan Healthcar has moved from fair to attractive, indicating a positive shift in its perceived value. The company appears to be undervalued, particularly when considering its current PE ratio of 42.12, an EV to EBITDA of 13.43, and a notably low EV to Book Value of 0.41. These ratios suggest that the market may not fully recognize the company's potential relative to its earnings and assets.<BR><BR>In comparison to its peers, Deccan Healthcar's valuation stands out; for instance, Sun Pharma has a PE ratio of 34.56 but is considered expensive, while Cipla, also rated attractive, has a significantly lower PE of 22.72. The PEG ratio of Deccan Healthcar is 0.00, which further emphasizes its undervaluation compared to peers like Divi's Lab, which is categorized as very expensive with a PEG of 1.78. Additionally, the company's stock has underperformed against the Sensex over various periods, which may contribute to its current attractive valuation status.

When is the next results date for Deccan Healthcar?

Deccan Healthcar will announce its results on 14 November 2025.

Deccan Healthcar is scheduled to declare its results on 14 November 2025.

How has been the historical performance of Deccan Healthcar?

Deccan Healthcar has experienced fluctuating financial performance, with net sales increasing from INR 33.17 crore in March 2022 to INR 75.06 crore in March 2025, but operating profit and cash flow remain negative, indicating ongoing operational challenges. Total assets and liabilities have both risen to INR 124.93 crore by March 2025.

Answer:<BR>The historical performance of Deccan Healthcar shows a fluctuating trend in key financial metrics over the past several years.<BR><BR>Breakdown:<BR>Deccan Healthcar's net sales have shown a consistent increase from INR 33.17 crore in March 2022 to INR 75.06 crore in March 2025. However, the total operating income has mirrored this growth, reaching INR 75.06 crore in March 2025. The raw material cost has also risen significantly, from INR 3.98 crore in March 2022 to INR 40.89 crore in March 2025, indicating increased operational expenses. The total expenditure, excluding depreciation, has escalated from INR 27.83 crore in March 2022 to INR 71.91 crore in March 2025. Consequently, the operating profit (PBDIT) has seen a decline from INR 5.34 crore in March 2022 to INR 3.16 crore in March 2025. Profit before tax has also decreased from INR 0.54 crore in March 2022 to INR 1.63 crore in March 2025, while profit after tax has fluctuated, reaching INR 1.16 crore in March 2025, down from INR 0.32 crore in March 2022. The company's total assets have increased from INR 90.63 crore in March 2022 to INR 124.93 crore in March 2025, alongside total liabilities rising from INR 90.63 crore to INR 124.93 crore in the same period. Cash flow from operating activities has remained negative, with a cash flow of -6.00 crore in March 2025, reflecting ongoing challenges in cash generation despite a net cash inflow of 0.00 crore in the same year.

Should I buy, sell or hold Deccan Health Care Ltd?

Which are the latest news on Deccan Healthcar?

Why is Deccan Health Care Ltd falling/rising?

As of 18-Jan, Deccan Health Care Ltd's stock price is Rs 13.50, reflecting a 2.32% decline and significant underperformance over the past year, with a 52.26% drop. The stock is trading near its 52-week low and below all moving averages, indicating a bearish trend and weak investor interest.

As of 18-Jan, Deccan Health Care Ltd's stock price is falling, currently at Rs 13.50, which reflects a decrease of Rs 0.32 or 2.32%. The stock has shown a significant decline over various periods, including a 1-month drop of 15.36% and a staggering 52.26% decrease over the past year. This underperformance is starkly contrasted with the Sensex, which has gained 8.47% over the same year.<BR><BR>The stock is currently trading close to its 52-week low, just 3.7% above it, and has underperformed its sector by 1.21% today. Additionally, Deccan Health Care Ltd is trading below its moving averages across all time frames, including 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend.<BR><BR>Investor participation has also declined, with a delivery volume drop of 70.33% compared to the 5-day average, suggesting a lack of interest among investors. Furthermore, the company has shown weak long-term fundamental strength, with an average Return on Equity (ROE) of only 1.43% and a poor EBIT to Interest ratio of 1.84, indicating challenges in servicing its debt.<BR><BR>Despite declaring positive results for the last three consecutive quarters, including a 28.51% growth in net sales over the latest six months, the overall financial health appears weak, with profits having fallen by 9% over the past year. This combination of factors contributes to the stock's current downward trajectory.